
Shares of drug developer Cargo Therapeutics CRGX.O rise 21% to $4.60 premarket
On Tuesday, co said it is reducing its workforce by about 90%
CRGX appointed Anup Radhakrishnan as interim CEO to lead the co through a potential merger or acquisition
As of December 31, 2024, co had about 167 full-time employees - SEC filing
Co also said it is stopping its experimental cancer therapy, CRG-023, and allogeneic platform
Earlier this year, co halted a mid-stage trial for cancer treatment
CRGX has $368.1 million in cash, as of December 31, 2024
CRGX fell 36.5% last year